Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.
The small-cap biopharmaceutical company announced a public stock offering.
Despite declines in the broader market, good news lifted shares of these companies.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.